Measurable Residual Disease Testing Using Next-Generation Sequencing in Acute Myeloid Leukemia
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Measurable residual disease (MRD) is an important prognostic indicator of AML and is critical for risk stratification of treatment decisions [1]. Detecting MRD in patients with morphologically determined marrow with <5% blasts is important for refining the risk classification of AML [1, 2]. MRD detection in AML enables refined outcome prediction, impending relapse identification, and early intervention [1]. Several laboratory techniques can be utilized for the sensitive and accurate detection of MRD in AML and other hematologic malignancies. In clinical laboratories, molecular diagnostic methods, such as FISH and reverse transcription (RT)-PCR, have been used for the detection of recurrent fusion genes [3-4]. Newer diagnostic technologies, including droplet digital PCR (ddPCR), multiparametric flow cytometry, and next-generation sequencing (NGS), enable sensitive detection of MRD (up to 10-3–10-6 leukemic cell burden) [1, 4-6].
Abstract
Measurable residual disease (MRD) is an important prognostic indicator of AML and is critical for risk stratification of treatment decisions [1]. Detecting MRD in patients with morphologically determined marrow with <5% blasts is important for refining the risk classification of AML [1, 2]. MRD detection in AML enables refined outcome prediction, impending relapse identification, and early intervention [1]. Several laboratory techniques can be utilized for the sensitive and accurate detection of MRD in AML and other hematologic malignancies. In clinical laboratories, molecular diagnostic methods, such as FISH and reverse transcription (RT)-PCR, have been used for the detection of recurrent fusion genes [3-4]. Newer diagnostic technologies, including droplet digital PCR (ddPCR), multiparametric flow cytometry, and next-generation sequencing (NGS), enable sensitive detection of MRD (up to 10-3–10-6 leukemic cell burden) [1, 4-6].
참고문헌 (12)
- Schuurhuis GJ, "Minimal", measurable residual disease in AML : a consensus document from the European LeukemiaNet MRD Working Party, 2018, pp.131, 1275~1291
- Panuzzo C, "Revealing the mysteries of acute myeloid leukemia : from quantitative PCR through next-generation sequencing and systemic metabolomic profiling", J Clin Med, 11, pp.483~ (2022)
- Wheeler FC, "Limited utility of fluorescence in situ hybridization for recurrent abnormalities in acute myeloid leukemia at diagnosis and follow-up", Am J Clin Pathol, 149, pp.418~424 (2018)
- Selim AG, "Molecular minimal residual disease monitoring in acute myeloid leukemia : challenges and future directions", J Mol Diagn, 20, pp.389~397 (2018)
- Hee-Jung Chung, "Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay", Annals of Laboratory Medicine, 40(1), pp.72~75 (2020), 대한진단검사의학회[DOI]
- 김현영, "Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma", Annals of Laboratory Medicine, 42(5), pp.558~565 (2022), 대한진단검사의학회[DOI]
- 김혜진, "Korean Society for Genetic Diagnostics Guidelines for Validation of Next-Generation Sequencing-Based Somatic Variant Detection in Hematologic Malignancies", Annals of Laboratory Medicine, 39(6), pp.515~523 (2019), 대한진단검사의학회[DOI]
- Zhong Yiming, "Application of Next Generation Sequencing in Laboratory Medicine", Annals of Laboratory Medicine, 41(1), pp.25~43 (2021), 대한진단검사의학회[DOI]
- Salipante SJ, "Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing", Mod Pathol, 27, pp.1438~1446 (2014)
- Levis MJ, "A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations", Blood Adv, 2, pp.825~831 (2018)
- Papaemmanuil E, "Genomic classification and prognosis in acute myeloid leukemia", N Engl J Med, 374, pp.2209~2221 (2016)
- 김진주, "Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia", Annals of Laboratory Medicine, 43(4), pp.328~336 (2023), 대한진단검사의학회[DOI]